Overexpression and Selective Anticancer Efficacy of ENO3 in STK11 Mutant Lung Cancers

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Oncogenic gain-of-function mutations are key biomarkers and drug targets in cancer therapy.
• Loss-of-function mutations in the tumor suppressor gene STK11 are significant in lung cancer progression but STK11 is not a direct therapeutic target.

Purpose of the Study:

• To identify cancer transcriptome signatures associated with STK11 loss-of-function mutations.
• To explore the potential of targeting ENO3 for lung cancer treatment in STK11-mutant cases.

Main Methods:

• Analysis of transcriptome data from cell lines and tissue samples using fold change and odds ratio analyses.
• Identification of gene expression markers including ENO3, TTC39C, LGALS3, and MAML2.
• Experimental validation of ENO3's role and its selective anticancer effect in STK11 mutant cells via knockdown studies.

Main Results:

• Several sensitive and specific gene expression markers were identified for STK11 loss-of-function mutations.
• ENO3 gene overexpression was confirmed as a direct consequence of STK11 loss-of-function.
• Knockdown of ENO3 demonstrated a selective anticancer effect in STK11 mutant lung cancer cells.

Conclusions:

• ENO3 is a potential biomarker for STK11 loss-of-function mutations in lung cancer.
• ENO3-based targeted therapy presents a promising therapeutic strategy for patients with STK11-mutant lung cancer.